Develop more sensitive and accurate biomarkers that improve diagnostic classification and prognostication and can be used in translational clinical trials.

Apply these findings in early phase clinical trials for patients with accelerating myeloproliferative disorders and mixed myelodysplastic syndrome/myeloproliferative disorders. Of particular current interest are DNA repair pathways and Parp inhibitors.